Raptor Pharmaceutical Provides PROCYSBI(TM) Launch Update and Second Quarter 2013 Financial Results
August 08, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 8, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today provided a launch update for PROCYSBI (cysteamine bitartrate) delayed-release capsules and financial...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
August 06, 2013 07:29 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 6, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, Raptor's Executive Vice President, Strategy and Chief Operating...
Raptor Pharmaceutical to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 8, 2013
August 01, 2013 07:29 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will release second quarter 2013 financial results after market close on Thursday,...
PROCYSBI(R) Receives Positive Opinion for Orphan Drug Exclusivity From the EU Committee for Orphan Medicinal Products
July 22, 2013 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 22, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it has received a positive opinion from the European Union (EU) Committee for Orphan...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
July 02, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., July 2, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's CEO, will present an overview of the company at...
Raptor Pharmaceutical's PROCYSBI(TM) Receives Positive Recommendation From CHMP
June 28, 2013 08:34 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 28, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced today that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a...
Raptor's PROCYSBI(TM) Receives U.S. Orphan Drug Exclusivity
June 25, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that the Office of Orphan Product Development at the Food and Drug Administration (FDA)...
Raptor's PROCYSBI(TM) Now Commercially Available in the U.S. for Nephropathic Cystinosis Patients
June 19, 2013 07:00 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 19, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that PROCYSBI™ (cysteamine bitartrate) delayed-release capsules are now available in...
Raptor Pharmaceutical to Present at Upcoming Investor Conference
June 12, 2013 07:30 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., June 12, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that Julie Anne Smith, executive vice president, strategy and chief operating officer of...
Raptor Pharmaceutical Reports First Quarter Calendar Year 2013 Financial Results
May 08, 2013 16:05 ET
|
Raptor Pharmaceutical Inc
NOVATO, Calif., May 8, 2013 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Raptor or the Company) (Nasdaq:RPTP) today reported financial results for its first quarter ended March 31,...